Aquestive Therapeutics (AQST) Total Liabilities (2017 - 2026)

Aquestive Therapeutics' Total Liabilities history runs 10 years deep, the most recent figure standing at $175.2 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 7.36% year-over-year to $175.2 million in Q1 2026; TTM through Mar 2026 was $175.2 million, a 7.36% increase from a year earlier, with the FY2025 full-year figure at $194.1 million, up 20.12% from the prior year.
• Total Liabilities slipped to $175.2 million in Q1 2026 per AQST's latest filing, from $194.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $194.1 million in Q4 2025 and bottomed at $149.7 million in Q1 2022.
• The 5-year median for Total Liabilities is $163.6 million (2023), against an average of $164.7 million.
• Across the five-year window, Total Liabilities soared 31.61% in 2022 and dropped 6.67% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $175.6 million in 2022, then decreased by 6.67% to $163.9 million in 2023, then slipped by 1.42% to $161.6 million in 2024, then gained by 20.12% to $194.1 million in 2025, then retreated by 9.74% to $175.2 million in 2026.
• Per Business Quant, the three latest AQST Total Liabilities figures stand at $175.2 million (Q1 2026), $194.1 million (Q4 2025), and $167.7 million (Q3 2025).